ArticleMedicine2026
Effect of uric acid and estimated glomerular filtration rate on the Fibrosis-4 index: A cross-sectional and cohort analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic steatosis and fibrosis present a significant public health burden, especially in China. Emerging evidence suggests an association between liver fibrosis and kidney function, indicating a potential relationship among uric acid (UA) levels, estimated glomerular filtration rate (eGFR), and the Fibrosis-4 (FIB-4) index. This retrospective cohort study investigates the correlation between UA, estimated GFR, and FIB-4 index in Chinese adults with metabolic dysfunction-associated steatotic liver disease (MASLD) using cross-sectional and longitudinal analyses. A total of 5051 adults with MASLD were included from 8857 individuals initially screened at the International Healthcare Center, Fourth Affiliated Hospital, Zhejiang University School of Medicine. The main outcome measure was the FIB-4 index. Among the 5051 participants (75.4% male; mean age, 42.3 years), the mean baseline eGFR was 98.7 mL/min/1.73 m2. Participants with lower eGFR had significantly older age and higher body mass index, systolic blood pressure, triglycerides, UA levels, and FIB-4 index than those with higher eGFR (P < .001 for all). In multivariable Cox regression analyses, each 1-standard deviation decrease in eGFR was associated with a 21% higher risk of an increased FIB-4 index (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.14-1.29; P < .001). Hyperuricemia (UA ≥ 420 μmol/L) was independently associated with a 38% higher risk of elevated FIB-4 (HR, 1.38; 95% CI: 1.23-1.55; P < .001). In the unadjusted model, a significant nonlinear dose-response relationship was observed between eGFR and FIB-4 (P for nonlinear trend < .001). However, after progressive adjustment for demographic variables, family history, and metabolic covariates, the nonlinear signal was markedly attenuated. Mediation analysis demonstrated that UA partially mediated the association between eGFR and FIB-4, accounting for 6.88% of the total effect. Reduced eGFR and hyperuricemia were independently associated with an elevated FIB-4 index in adults with MASLD, with a nonlinear relationship indicating a greater liver fibrosis risk in individuals with moderate to severe renal impairment (eGFR < 60 mL/min/1.73 m2). Partial mediation by UA suggests that metabolic dysregulation contributes to the kidney-liver interaction. Routine assessment of eGFR and UA may improve liver fibrosis risk stratification in patients with MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.